Home
>
US Stocks
>
Catalyst Pharmaceuticals Inc
Catalyst Pharmaceuticals Inc
CPRX

Catalyst Pharmaceuticals Inc

$6.0412.9%

1D

1W

1M

1Y

3Y

5Y

Key Stats

Open
6
Today Low/High
5.98 / 6.09
52 Week Low/High
$2.88 / $6.24
Market Cap
$588.01M

Company Details

Catalyst Pharmaceuticals is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, including Lambert-Eaton myasthenic syndrome (LEMS), anti-MuSK antibody positive myasthenia gravis (MuSK-MG) and other neurological and neuromuscular disorders. Catalyst's New Drug Application for Firdapse® (amifampridine) 10 mg tablets for the treatment of adults with LEMS was approved in 2018 by the U.S. Food & Drug Administration ('FDA'), and Firdapse is now commercially available in the United States. Further, Canada's national healthcare regulatory agency, Health Canada, recently approved the use of Firdapse® (amifampridine) for the treatment of patients in Canada with LEMS.
Organisation
Catalyst Pharmaceuticals Inc
Headquaters
Coral Gables, Florida, US
Employees
74
Industry
Health Technology
CEO
Patrick McEnany

Discover more

Frequently Asked Questions

What is Catalyst Pharmaceuticals Inc share price today

Can Indians buy Catalyst Pharmaceuticals Inc shares?

How can I buy Catalyst Pharmaceuticals Inc shares from India?

Can Fractional shares of Catalyst Pharmaceuticals Inc be purchased?

What are the documents required to start investing in Catalyst Pharmaceuticals Inc stocks?

We are a SEBI registered investement advisor